Sign In
Buy GNLX
$3.00
+0.0500 (+1.69%)
At Close: Jun 03, 2026
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
04:15pm, Thursday, 07'th May 2026
-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
04:15pm, Thursday, 19'th Mar 2026
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in r
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
04:00pm, Monday, 12'th Jan 2026
WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
09:13am, Thursday, 08'th Jan 2026
WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwr
Genelux Corporation Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 07'th Jan 2026
WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a p
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
08:00am, Friday, 02'nd Jan 2026
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.,
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
04:20pm, Wednesday, 05'th Nov 2025
-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --
Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates
04:20pm, Thursday, 07'th Aug 2025
WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter
WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
01:00pm, Monday, 02'nd Jun 2025
Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
04:10pm, Tuesday, 06'th May 2025
WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
04:10pm, Friday, 28'th Mar 2025
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer –
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
10:36am, Friday, 28'th Mar 2025
Genelux Corporation (GNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
08:31am, Tuesday, 25'th Mar 2025
WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underw
Genelux Corporation Announces New Chief Financial Officer
06:45am, Monday, 03'rd Feb 2025
WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the compa
